COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Valuation Ratios Analysis including PE, PB, PS, EV/EBITDA. Analyze if 3349.T stock is undervalued compared to peers/competitors, industry and sector standards or based on Value Investing Principles.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Valuation Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.

Price-to-Earnings Ratio (P/E)

30.52

Increased from previous period

P/E 1.25-1.5x 2127.T's 20.99. Bill Ackman would scrutinize if premium is justified by better prospects.

Price-to-Sales Ratio (P/S)

2.64

Decreased from previous period

P/S less than half of 2127.T's 21.35. Joel Greenblatt would verify if margins support this discount.

Price-to-Book Ratio (P/B)

2.81

Decreased from previous period

P/B 50-75% of 2127.T's 4.94. Bruce Berkowitz would examine if asset composition explains the gap.

Price-to-Free Cash Flow Ratio

64.30

Decreased from previous period

P/FCF of 64.30 while 2127.T has no FCF. Bruce Berkowitz would examine cash flow quality advantage.

Price-to-Operating Cash Flow Ratio

64.30

Decreased from previous period

P/OCF of 64.30 while 2127.T has no operating cash flow. Bruce Berkowitz would examine operational advantage.

Price-to-Fair Value

2.81

Decreased from previous period

Fair value ratio 50-75% of 2127.T's 4.94. Bruce Berkowitz would examine if business quality explains the gap.

Earnings Yield

0.82%

Decreased from previous period

Earnings yield 50-75% of 2127.T's 1.19%. Martin Whitman would scrutinize if lower yield reflects better quality.

Free Cash Flow Yield

1.56%

Increased from previous period

FCF yield of 1.56% while 2127.T has no FCF. Bruce Berkowitz would examine cash flow quality advantage.

Select Chart Metric:

3349.T Valuation Analysis - Compare Against 2127.T

Comparison against 2127.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Price-to-Earnings Ratio (P/E)

30.52

Increased from previous period

P/E 1.25-1.5x 2127.T's 20.99. Bill Ackman would scrutinize if premium is justified by better prospects.

Price-to-Sales Ratio (P/S)

2.64

Decreased from previous period

P/S less than half of 2127.T's 21.35. Joel Greenblatt would verify if margins support this discount.

Price-to-Book Ratio (P/B)

2.81

Decreased from previous period

P/B 50-75% of 2127.T's 4.94. Bruce Berkowitz would examine if asset composition explains the gap.

Price-to-Free Cash Flow Ratio

64.30

Decreased from previous period

P/FCF of 64.30 while 2127.T has no FCF. Bruce Berkowitz would examine cash flow quality advantage.

Price-to-Operating Cash Flow Ratio

64.30

Decreased from previous period

P/OCF of 64.30 while 2127.T has no operating cash flow. Bruce Berkowitz would examine operational advantage.

Price-to-Fair Value

2.81

Decreased from previous period

Fair value ratio 50-75% of 2127.T's 4.94. Bruce Berkowitz would examine if business quality explains the gap.

Earnings Yield

0.82%

Decreased from previous period

Earnings yield 50-75% of 2127.T's 1.19%. Martin Whitman would scrutinize if lower yield reflects better quality.

Free Cash Flow Yield

1.56%

Increased from previous period

FCF yield of 1.56% while 2127.T has no FCF. Bruce Berkowitz would examine cash flow quality advantage.

Select Chart Metric: